Skip to content
Intrinsic value · Buy/Sell verdict · scores — free· 1403 Nifty 500 stocks· EOD 2026-06-19

Alpa Laboratories Limited

ALPA · NSE · Healthcare

₹68.11
+0.25 (+0.37%)
Buy zoneHold
The bottom line

StocksWizard rates Alpa Laboratories Limited a Hold, scoring 54/100 on our blended model. At ₹68.11 it trades below our blended DCF and relative-multiples fair value of ₹136.22, implying roughly 100% upside to that estimate — we read the stock as undervalued by 100%. Financial health scores 54/100 (grade C), in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. It clears 7 of 12 investability checks, with durability 61, valuation 100 and momentum 29 on our 0–100 scales.

These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Our verdict
Hold54/100
Quality61
Valuation100
Momentum29
Financial trend0
Intrinsic value
Our fair value
₹136.22
Undervalued by 100%
Price ₹68.11Range ₹54.53₹147.12

With a 20% margin of safety, our buy-below price is ₹108.98. Low-confidence estimate — limited data.

C
Financial health 54/100
Altman Z 3.15 · Safe zone

Piotroski F-score 4/9 — quality of earnings & balance sheet.

Investability checklist

Passed 7 of 12 checks58/100
  • ROE above 15%8.4%
  • Low debt (D/E < 0.5)0.01x
  • Positive free cash flow
  • Revenue growth > 10%-21%
  • Earnings growing
  • Net margin ≥ 10%14.2%
  • Current ratio > 1.54.01
  • Below our fair value
  • Margin of safety ≥ 20%
  • Above 200-day average
  • Above 50-day average
  • Positive 1-year return
  • Altman Z in safe zoneZ 3.15
  • Piotroski ≥ 74/9

1-year price

EOD · 2026-06-19
1W
-2.3%
1M
-2.1%
3M
+14.0%
6M
-15.5%
1Y

Our scores

Durability61
Valuation100
Momentum29

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Quarterly results

4Q2017₹18 Cr revenue
Net profit ₹0 Cr0% margin
1Q2018₹18 Cr revenue
Net profit ₹-3 Cr-15% margin
Revenue Net profitLatest revenue QoQ +2%

Annual financials

2017₹72 Cr revenue
Net profit ₹0 Cr0% margin
2018₹67 Cr revenue
Net profit ₹5 Cr7% margin
Revenue Net profitLatest revenue YoY -7%

Shareholding

Promoter57.3%
Institutions0.0%
Public & other42.7%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹143 Cr
P/E ratio
9.6
P/B ratio
2.11
EPS (TTM)
₹7.13
ROE
8.4%
Debt / Equity
0.01x
Profit margin
14.2%
Free cash flow
₹9 Cr
52-week high
₹104.58
-34.87% from high
52-week low
₹46.46
Dividend yield
Beta
0.95

SWOT snapshot

Strengths

  • Lightly leveraged balance sheet.
  • Financially solid — Altman Z 3.15.

Weaknesses

  • Price below its 200-day moving average (downtrend).

Opportunities

  • Trading in our value buy zone versus sector peers.
  • Trades ~100% below our estimated fair value.

About Alpa Laboratories Limited

Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It provides formulations that address various therapeutic segments. The company was incorporated in 1988 and is based in Indore, India.

More in Healthcare

All stocks

Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.